((自动化翻译由路透提供，请见免责声明 )) (更新)
12月12日 - ** 药物开发商Keros Therapeutics 股价下跌约77%，跌至2020年4月纳斯达克上市以来的 最低水平 15.96美元。
** KROS表示，由于心脏周围液体积聚，已停止 (link) 每公斤 3.0毫克和 每公斤 4.5毫克剂量的高血压治疗药物的中期研究。
** 1.5毫克/公斤组的用药将在独立监督委员会进行风险效益审查后继续进行 - KROS
** 公司已向美国 FDA 发出通知，预计将于 2025 年第二季度提交所有治疗组的数据 - KROS
** 包括本交易日的走势在内，该股今年已累计下跌58.6
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.